The prescription medical food serum-derived bovine immunoglobulin/protein isolate (SBI) could be effective in as many as 90% of patients with refractory pouchitis, according to a new study. The investigators said the product should be considered early in the management of ulcerative colitis (UC) patients with pouchitis.
Konstantinos A. Papadakis, MD, consultant and professor of medicine at Mayo Clinic, in Rochester, Minn., called the findings “intriguing.” However, randomized,